Phase II study of doxercalciferol for the treatment of myelodysplastic syndrome.
作者信息
Petrich Adam, Kahl Brad, Bailey Howard, Kim Kyungmann, Turman Nancy, Juckett Mark
机构信息
Department of Medicine, University of Wisconsin Comprehensive Cancer Center, University of Wisconsin, Madison, WI, USA.
出版信息
Leuk Lymphoma. 2008 Jan;49(1):57-61. doi: 10.1080/10428190701713648.
Abstract
We conducted a phase II trial of doxercalciferol, a vitamin D2 analogue, in 15 patients with MDS. Each received doxercalciferol 12.5 microg orally daily for 12 weeks. Nine of 15 patients completed the prescribed course and of these, six had stable disease. No patient had a response (IWG criteria) and overall eight patients experienced progressive disease while on therapy. Two patients with chronic myelomonocytic leukemia (CMML) had a marked rise in monocytes on study. Overall the treatment was well tolerated. One patient was removed from study due to hypercalcemia. We conclude that short-term treatment with doxercalciferol has limited activity in patients with MDS.
摘要
相似文献
1
Phase II study of doxercalciferol for the treatment of myelodysplastic syndrome.
Leuk Lymphoma. 2008 Jan;49(1):57-61. doi: 10.1080/10428190701713648.
2
Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.阿扎胞苷治疗失败后接受地西他滨治疗的高危骨髓增生异常综合征（MDS）和晚期慢性粒单核细胞白血病（CMML）患者的结局
Leuk Res. 2015 May;39(5):501-4. doi: 10.1016/j.leukres.2015.02.004. Epub 2015 Feb 16.
3
Phase I/II clinical study of topotecan and cytarabine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia and acute myeloid leukemia.拓扑替康与阿糖胞苷用于骨髓增生异常综合征、慢性粒单核细胞白血病和急性髓细胞白血病患者的I/II期临床研究。
Leuk Lymphoma. 2004 Apr;45(4):699-704. doi: 10.1080/10428190310001593175.
4
Real Life Data on Efficacy and Safety of Azacitidine Therapy for Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia.真实世界中阿扎胞苷治疗骨髓增生异常综合征、慢性粒单核细胞白血病和急性髓系白血病的疗效和安全性数据。
Pathol Oncol Res. 2019 Jul;25(3):1175-1180. doi: 10.1007/s12253-018-00574-0. Epub 2019 Jan 6.
5
Vasculitis associated with myelodysplastic syndrome and chronic myelomonocytic leukemia: French multicenter case-control study.骨髓增生异常综合征和慢性粒单核细胞白血病相关血管炎：法国多中心病例对照研究。
Semin Arthritis Rheum. 2020 Oct;50(5):879-884. doi: 10.1016/j.semarthrit.2020.07.002. Epub 2020 Jul 11.
6
Vitamin D(2) analog (Paricalcitol; Zemplar) for treatment of myelodysplastic syndrome.
Leuk Res. 2005 Nov;29(11):1259-62. doi: 10.1016/j.leukres.2005.04.003. Epub 2005 Apr 26.
7
8
On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia.关于洛那法尼在骨髓增生异常综合征和慢性粒单核细胞白血病中的应用。
Leukemia. 2008 Sep;22(9):1707-11. doi: 10.1038/leu.2008.156. Epub 2008 Jun 12.
9
Intractable pruritus in chronic myelomonocytic leukaemia and myelodysplastic syndromes: a case series.慢性粒单核细胞白血病和骨髓增生异常综合征中的难治性瘙痒：病例系列
BMJ Case Rep. 2019 Oct 23;12(10):e232480. doi: 10.1136/bcr-2019-232480.
10
Eltrombopag Use in Patients With Chronic Myelomonocytic Leukemia (CMML): A Cautionary Tale.艾曲泊帕在慢性粒单核细胞白血病（CMML）患者中的应用：一个警示故事。
Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S64-6. doi: 10.1016/j.clml.2016.02.009.
引用本文的文献
1
Targeting the Tumor Microenvironment in Acute Myeloid Leukemia: The Future of Immunotherapy and Natural Products.靶向急性髓系白血病的肿瘤微环境：免疫疗法与天然产物的未来
Biomedicines. 2022 Jun 14;10(6):1410. doi: 10.3390/biomedicines10061410.
2
Effect of Vitamin D on Graft-versus-Host Disease.维生素D对移植物抗宿主病的影响。
Biomedicines. 2022 Apr 24;10(5):987. doi: 10.3390/biomedicines10050987.
3
A novel vitamin D gene therapy for acute myeloid leukemia.一种用于急性髓系白血病的新型维生素D基因疗法。
Transl Oncol. 2020 Dec;13(12):100869. doi: 10.1016/j.tranon.2020.100869. Epub 2020 Sep 18.
4
Phosphorylation of Human Retinoid X Receptor α at Serine 260 Impairs Its Subcellular Localization, Receptor Interaction, Nuclear Mobility, and 1α,25-Dihydroxyvitamin D3-dependent DNA Binding in Ras-transformed Keratinocytes.人视黄酸X受体α在丝氨酸260处的磷酸化损害其在Ras转化角质形成细胞中的亚细胞定位、受体相互作用、核移动性以及1α,25-二羟基维生素D3依赖性DNA结合。
J Biol Chem. 2017 Jan 27;292(4):1490-1509. doi: 10.1074/jbc.M116.758185. Epub 2016 Nov 16.
5
Vitamin D in hematological disorders and malignancies.血液系统疾病和恶性肿瘤中的维生素D
Eur J Haematol. 2017 Mar;98(3):187-197. doi: 10.1111/ejh.12818. Epub 2016 Nov 21.
6
Enhancement of arabinocytosine (AraC) toxicity to AML cells by a differentiation agent combination.分化剂组合增强阿糖胞苷（AraC）对急性髓系白血病（AML）细胞的毒性作用。
J Steroid Biochem Mol Biol. 2016 Nov;164:72-78. doi: 10.1016/j.jsbmb.2015.08.023. Epub 2015 Aug 28.
7
The role of vitamin D in hematologic disease and stem cell transplantation.维生素 D 在血液系统疾病和干细胞移植中的作用。
Nutrients. 2013 Jun 18;5(6):2206-21. doi: 10.3390/nu5062206.
8
Clinical experience using vitamin d and analogs in the treatment of myelodysplasia and acute myeloid leukemia: a review of the literature.维生素D及其类似物治疗骨髓增生异常综合征和急性髓系白血病的临床经验：文献综述
Leuk Res Treatment. 2012;2012:125814. doi: 10.1155/2012/125814. Epub 2012 Jul 30.
9
Is there a role for differentiating therapy in non-APL AML?在非 APL AML 中是否有区分治疗的作用？
Best Pract Res Clin Haematol. 2010 Dec;23(4):503-8. doi: 10.1016/j.beha.2010.09.014. Epub 2010 Nov 23.
本文引用的文献
1
Vitamin D(2) analog (Paricalcitol; Zemplar) for treatment of myelodysplastic syndrome.
Leuk Res. 2005 Nov;29(11):1259-62. doi: 10.1016/j.leukres.2005.04.003. Epub 2005 Apr 26.
2
19-Nor-1,25(OH)2D2 (a novel, noncalcemic vitamin D analogue), combined with arsenic trioxide, has potent antitumor activity against myeloid leukemia.19-去甲-1,25-二羟维生素D2（一种新型非钙调维生素D类似物）与三氧化二砷联合使用，对髓系白血病具有强大的抗肿瘤活性。
Cancer Res. 2005 Mar 15;65(6):2488-97. doi: 10.1158/0008-5472.CAN-04-2800.
3
Phase II study of 1alpha-hydroxyvitamin D(2) in the treatment of advanced androgen-independent prostate cancer.1α-羟基维生素D₂治疗晚期雄激素非依赖性前列腺癌的II期研究。
Clin Cancer Res. 2003 Sep 15;9(11):4077-83.
4
5
Novel ring A stereoisomers of 2-methyl-1alpha,25-dihydroxyvitamin D(3) and 2-methyl-20-epi-1alpha,25-dihydroxyvitamin D(3): transactivation of target genes and modulation of differentiation in human promyelocytic leukemia (HL-60) cells.新型2-甲基-1α,25-二羟基维生素D(3)和2-甲基-20-表-1α,25-二羟基维生素D(3)的A环立体异构体：在人早幼粒细胞白血病(HL-60)细胞中对靶基因的反式激活及分化调节
Biochem Pharmacol. 2000 Mar 15;59(6):691-702. doi: 10.1016/s0006-2952(99)00357-3.
6
Drug development in prostate cancer.前列腺癌的药物研发
Semin Oncol. 1999 Apr;26(2):217-26.
7
Myelodysplasia.骨髓发育异常
N Engl J Med. 1999 May 27;340(21):1649-60. doi: 10.1056/NEJM199905273402107.
8
1,25(OH)2D3-modulated calcium induced keratinocyte differentiation.1,25-二羟维生素D3调节的钙诱导角质形成细胞分化。
J Investig Dermatol Symp Proc. 1996 Apr;1(1):22-7.
9
Vitamin D treatment in myelodysplastic syndromes.
Br J Haematol. 1998 Mar;100(3):516-20. doi: 10.1046/j.1365-2141.1998.00598.x.
10
International scoring system for evaluating prognosis in myelodysplastic syndromes.评估骨髓增生异常综合征预后的国际评分系统。
Blood. 1997 Mar 15;89(6):2079-88.
Zotero 插件